Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD2 | Q9Y5L3 | 3/20 | 0.58 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.47 |
| ▸ | TK2 | O00142 | 3/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.38 |
| ▸ | AHCY | P23526 | 1/20 | 0.37 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15859373 | 1.00 | ENTPD2 (0.58) | ENTPD2ENTPD1TK2P2RY14AHCY | |
| SCHEMBL13211038 | 1.00 | ENTPD2 (0.58) | ENTPD2ENTPD1TK2P2RY14AHCY | |
| SCHEMBL13210991 | 0.86 | ENTPD2 (0.78) | ENTPD2ENTPD1P2RY14 | |
| SCHEMBL3025686 | 0.86 | ENTPD2 (0.78) | ENTPD2ENTPD1P2RY14 | |
| SCHEMBL13211017 | 0.82 | ENTPD1 (0.72) | ENTPD2ENTPD1TK2P2RY14TK1 | |
| SCHEMBL3027286 | 0.81 | ENTPD2 (0.70) | ENTPD2ENTPD1P2RY14 | |
| SCHEMBL14383976 | 0.81 | ENTPD2 (0.70) | ENTPD2ENTPD1P2RY14 | |
| SCHEMBL13210985 | 0.81 | ENTPD2 (0.70) | ENTPD2ENTPD1P2RY14 | |
| SCHEMBL14387175 | 0.81 | ENTPD2 (0.70) | ENTPD2ENTPD1P2RY14 | |
| SCHEMBL13211032 | 0.81 | ENTPD2 (0.47) | ENTPD2ENTPD1TK2AHCYTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | ENTPD2 10/4885ENTPD1 3/4885TK2 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.